Carbapenem-Resistant Enterobacteriaceae: A Retrospective Review of Presentation, Treatment, and Clinical Outcomes in a Tertiary Care Referral Hospital
- PMID: 36004017
- PMCID: PMC9392368
- DOI: 10.7759/cureus.27094
Carbapenem-Resistant Enterobacteriaceae: A Retrospective Review of Presentation, Treatment, and Clinical Outcomes in a Tertiary Care Referral Hospital
Abstract
Background: Carbapenem-resistant Enterobacteriaceae (CRE) is an emerging infectious threat with an increasing incidence locally and worldwide. It carries a high morbidity and mortality; focusing on this topic should be a priority in clinical research as local data are not widely available. The objective of this study is to describe the presentation, risk factors, treatment pattern and clinical outcomes associated with CRE infections.
Methods: We conducted a cross-sectional retrospective study in a single center tertiary referral hospital. We included adult patients above 18 years of age with infection due to CRE between January 1, 2018, to December 30, 2019. Results: During this period, 76 cases were studied. The mean age of the cases was 54 years. The majority were immunosuppressed and admitted to the intensive care unit. The most frequent risk factors associated with CRE infection among study subjects included prior antibiotics in the preceding three months and prior hospital admission in the last one year. Klebsiella pneumoniae (77%) represented the most isolated organism. All-cause intensive care unit and in-hospital mortality were significantly higher among patients with pneumonia and bacteremia. Conclusions: CRE infections are associated with higher morbidity and mortality specifically in patients who presented with pneumonia and bacteremia. High resistance rate and limited treatment options have made a great variability in the clinical practice. Appropriate definitive treatment of CRE infections, strict infection control measures, and antimicrobial stewardship program activation are essential.
Keywords: carbapenem-resistant enterobacteriaceae; intensive care; mortality; risk factors; saudi.
Copyright © 2022, Al Khamis et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.Ann Clin Microbiol Antimicrob. 2018 Mar 23;17(1):13. doi: 10.1186/s12941-018-0267-8. Ann Clin Microbiol Antimicrob. 2018. PMID: 29571291 Free PMC article.
-
Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018.Eur J Clin Microbiol Infect Dis. 2020 Jul;39(7):1287-1294. doi: 10.1007/s10096-020-03845-4. Epub 2020 Mar 2. Eur J Clin Microbiol Infect Dis. 2020. PMID: 32124106
-
Demographic, clinical, and outcome characteristics of carbapenem-resistant Enterobacteriaceae over a 10-year period (2010-2020) in Oman.IJID Reg. 2022 Aug 4;4:165-170. doi: 10.1016/j.ijregi.2022.08.001. eCollection 2022 Sep. IJID Reg. 2022. PMID: 36059919 Free PMC article.
-
An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.Infect Dis Ther. 2020 Dec;9(4):769-784. doi: 10.1007/s40121-020-00344-z. Epub 2020 Oct 6. Infect Dis Ther. 2020. PMID: 33025557 Free PMC article. Review.
-
[Clinical impact of infections with carbapenem-resistant enterobacteriaceae in liver transplant recipients].Z Gastroenterol. 2015 Nov;53(11):1276-87. doi: 10.1055/s-0041-106855. Epub 2015 Nov 12. Z Gastroenterol. 2015. PMID: 26562402 Review. German.
Cited by
-
Bacteremia in the Gulf Cooperation Council Region: A Review of the Literature 2013-2023.Infect Drug Resist. 2025 May 7;18:2329-2355. doi: 10.2147/IDR.S497241. eCollection 2025. Infect Drug Resist. 2025. PMID: 40357416 Free PMC article. Review.
-
Clinical Predispositions, Features, and Outcomes of Infections with Carbapenem-resistant Enterobacterales among Critical Care Patients.Indian J Crit Care Med. 2025 Jan;29(1):36-44. doi: 10.5005/jp-journals-10071-24876. Epub 2024 Dec 30. Indian J Crit Care Med. 2025. PMID: 39802247 Free PMC article.
-
Susceptibility of various Gram-negative bacteria to antibacterial agents: SMART in China 2019-2020.BMC Microbiol. 2024 Dec 19;24(1):524. doi: 10.1186/s12866-024-03526-8. BMC Microbiol. 2024. PMID: 39695970 Free PMC article.
-
Carbapenemase-Producing Escherichia coli: Comparison of a Novel Rapid Lateral Flow Assay With the Polymerase Chain Reaction (PCR) and Antimicrobial Resistance Pattern.Cureus. 2024 Sep 8;16(9):e68941. doi: 10.7759/cureus.68941. eCollection 2024 Sep. Cureus. 2024. PMID: 39381457 Free PMC article.
References
-
- Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P. http://ccforum.com/content/14/3/R113. Crit Care. 2010;14:113. - PMC - PubMed
-
- The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Nordmann P, Poirel L. http://10.1111/1469-0691.12719. Clin Microbiol Infect. 2014;20:821–830. - PubMed
-
- Epidemiology of carbapenem resistance Enterobacterales. Abou-assy RS, Aly MM, Amashah RH, Jastaniah SD, Deen HM. J Contemp Med Sci. 2022;8:9.
LinkOut - more resources
Full Text Sources